January 16, 2020 / 9:58 AM / 10 days ago

BRIEF-Grifols To Launch Tavlesse In Europe

Jan 16 (Reuters) - Grifols SA:

* SAYS EUROPEAN COMMISSION HAS APPROVED TAVLESSE (FOSTAMATINIB) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS

* SAYS GRIFOLS GAINED EXCLUSIVE RIGHTS TO TAVLESSE IN ITP AND OTHER PIPELINE INDICATIONS IN EUROPE AND TURKEY AS A RESULT OF THE COLLABORATION AND LICENSE AGREEMENT REACHED WITH RIGEL PHARMACEUTICALS IN JANUARY 2019

* SAYS TAVLESSE LAUNCH IS EXPECTED TO BE IN Q2 OF THIS YEAR

Source text: bit.ly/30rR772

Further company coverage:

Gdansk Newsroom

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below